文献リスト

1）Wu LM, Xu JR, Gu HY, et al. Is liver-specific gadoxetic acid-enhanced magnetic resonance imaging a reliable tool for detection of hepatocellular carcinoma in patients with chronic liver disease? Dig Dis Sci. 2013; 58: 3313-25

2）Liu X, Zou L, Liu F, et al. Gadoxetic acid disodium-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. PLoS One. 2013; 8: e70896

3）Junqiang L, Yinzhong W, Li Z, et al. Gadoxetic acid disodium (Gd-EOBDTPA)-enhanced magnetic resonance imaging for the detection of hepatocellular carcinoma: a meta-analysis. J Magn Reson Imaging. 2014; 39: 1079-87

4）Chen L, Zhang J, Zhang L, et al. Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases. PLoS One. 2012; 7: e48681

5）Higaki A, Tamada T, Sone T, et al. Potential clinical factors affecting hepatobiliary enhancement at Gd-EOB-DTPA-enhanced MR imaging. Magn Reson Imaging. 2012; 30: 689-93

6）Kumada T, Toyoda H, Tada T, et al. Evolution of hypointense hepatocellular nodules observed only in the hepatobiliary phase of gadoxetate disodium-enhanced MRI. AJR Am J Roentgenol. 2011; 197: 58-63

7）Motosugi U, Ichikawa T, Sano K, et al. Outcome of hypovascular hepatic nodules revealing no gadoxetic acid uptake in patients with chronic liver disease. J Magn Reson Imaging. 2011; 34: 88-94

8）Kim YK, Lee WJ, Park MJ, et al. Hypovascular hypointense nodules on hepatobiliary phase gadoxetic acid-enhanced MR images in patients with cirrhosis: potential of DW imaging in predicting progression to hypervascular HCC. Radiology. 2012; 265: 104-14

9）Takechi M, Tsuda T, Yoshioka S, et al. Risk of hypervascularization in small hypovascular hepatic nodules showing hypointense in the hepatobiliary phase of gadoxetic acid-enhanced MRI in patients with chronic liver disease. Jpn J Radiol. 2012; 30: 743-51

10）Inoue T, Hyodo T, Murakami T, et al. Hypovascular hepatic nodules showing hypointense on the hepatobiliary-phase image of Gd-EOB-DTPA-enhanced MRI to develop a hypervascular hepatocellular carcinoma: a nationwide retrospective study on their natural course and risk factors. Dig Dis. 2013; 31: 472-9

11）Hyodo T, Murakami T, Imai Y, et al. Hypovascular nodules in patients with chronic liver disease: risk factors for development of hypervascular hepatocellular carcinoma. Radiology. 2013; 266: 480-90

12）Yamamoto A, Ito K, Tamada T, et al. Newly developed hypervascular hepatocellular carcinoma during follow-up periods in patients with chronic liver disease: observation in serial gadoxetic acid-enhanced MRI. AJR Am J Roentgenol. 2013; 200: 1254-60

13）Ichikawa S, Ichikawa T, Motosugi U, et al. Presence of a hypovascular hepatic nodule showing hypointensity on hepatocyte-phase image is a risk factor for hypervascular hepatocellular carcinoma. J Magn Reson Imaging. 2014; 39: 293-7

14）Narita M, Hatano E, Arizono S, et al. Expression of OATP1B3 determines uptake of Gd-EOB-DTPA in hepatocellular carcinoma. J Gastroenterol. 2009; 44: 793-8

15）Kitao A, Zen Y, Matsui O, et al. Hepatocellular carcinoma：signal intensity at gadoxetic acid-enhanced MR Imaging – correlation with molecular transporters and histopathologic features. Radiology. 2010; 256: 817-26

16）Kitao A, Matsui O, Yoneda Y, et al. Hypervascular hepatocellular carcinoma: correlation between biologic features and signal intensity on gadoxetic acid-enhanced MR images. Radiology. 2012; 265: 780-9

17）Yoneda N, Matsui O, Kitao A, et al. Hypervascular hepatocellular carcinomas showing hyperintensity on hepatobiliary phase of gadoxetic acid-enhanced magnetic resonance imaging: a possible subtype with mature hepatocyte nature. Jpn J Radiol. 2013; 31: 480-90

18）Sekine S, Ogawa R, Ojima H, et al. Expression of SLCO1B3 is associated with intratumoral cholestasis and CTNNB1 mutations in hepatocellular carcinoma. Cancer Sci. 2011; 102: 1742-7

19）Mao TL, Chu JS, Jeng YM, et al. Expression of mutant nuclear beta-catenin correlates with non-invasive hepatocellular carcinoma, absence of portal vein spread, and good prognosis. J Pathol. 2001; 193: 95-101

20）Motosugi U, Ichikawa T, Sano K, et al. Magnetic resonance elastography of the liver: preliminary results and estimation of inter-rater reliability. Jpn J Radiol. 2010; 28: 623-7

21）Huwart L, Sempoux C, Salameh N, et al. Liver fibrosis: noninvasive assessment with MR elastography versus aspartate aminotransferase-to-platelet ratio index. Radiology. 2007; 245: 458-66

22）Motosugi U, Ichikawa T, Sou H, et al. Effects of gadoxetic acid on liver elasticity measurement by using magnetic resonance elastography. Magn Reson Imaging. 2012; 30: 128-32

23）Ichikawa S, Motosugi U, Ichikawa T, et al. Magnetic resonance elastography for staging liver fibrosis in chronic hepatitis C. Magn Reson Med Sci. 2012; 11: 291-7

24）Shi Y, Guo Q, Xia F, et al. MR Elastography for the Assessment of Hepatic Fibrosis in Patients with Chronic Hepatitis B Infection: Does Histologic Necroinflammation Influence the Measurement of Hepatic Stiffness?　Radiology. 2014; 132592

25）Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology. 2008; 135: 32-40

26）Yoon JH, Lee JM, Joo I, et al. Hepatic Fibrosis: Prospective Comparison of MR Elastography and US Shear Wave Elastography for Evaluation. Radiology. 2014 Jul 7.[Epub ahead of print]

27）Kanematsu M, Goshima S, Watanabe H, et al. Diffusion/perfusion MR imaging of the liver: practice, challenges, and future. Magn Reson Med Sci. 2012; 11: 151-61

28）Wang Q-B, Zhu H, Liu H-L, et al. Performance of magnetic resonance elastography and diffusion-weighted imaging for the staging of hepatic fibrosis: A meta-analysis. Hepatology. 2012; 56: 239-47

29）Motosugi U, Ichikawa T, Sou H, et al. Liver parenchymal enhancement of hepatocyte-phase images in Gd-EOB-DTPA-enhanced MR imaging: which biological markers of the liver function affect the enhancement? J Magn Reson Imaging. 2009; 30: 1042-6

30）Watanabe H, Kanematsu M, Goshima S, et al. Staging hepatic fibrosis: comparison of gadoxetate disodium-enhanced and diffusion-weighted MR imaging – preliminary observations. Radiology. 2011; 259: 142-50

31）Motosugi U, Ichikawa T, Oguri M, et al. Staging liver fibrosis by using liver-enhancement ratio of gadoxetic acid-enhanced MR imaging: comparison with aspartate aminotransferase-to-platelet ratio index. Magn Reson Imaging. 2011; 29: 1047-52

32）Chen BB, Hsu CY, Yu CW, et al. Clinical and histologic implications of delayed hepatobiliary enhancement on magnetic resonance imaging with gadolinium ethoxybenzyl diethylenetriaminepentaacetic Acid. Invest Radiol. 2012; 47: 649-55

33）Wang YX, Yuan J, Chu ES, et al. T1rho MR imaging is sensitive to evaluate liver fibrosis: an experimental study in a rat biliary duct ligation model. Radiology. 2011; 259: 712-9

34）Allkemper T, Sagmeister F, Cicinnati V, et al. Evaluation of fibrotic liver disease with whole-liver T1ρ MR imaging: a feasibility study at 1.5 T. Radiology. 2014; 271: 408-15

35）Rauscher I, Eiber M, Ganter C, et al. Evaluation of T1ρ as a potential MR biomarker for liver cirrhosis: comparison of healthy control subjects and patients with liver cirrhosis. Eur J Radiol. 2014; 83: 900-4

36）Bohte AE, van Werven JR, Bipat S, et al. The diagnostic accuracy of US, CT, MRI and 1H-MRS for the evaluation of hepatic steatosis compared with liver biopsy: a meta-analysis. Eur Radiol. 2011; 21: 87-97

37）Hernaez R, Lazo M, Bonekamp S, et al. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology. 2011; 54: 1082-90

38）Masaki K, Takaki S, Hyogo H, et al. Utility of controlled attenuation parameter measurement for assessing liver steatosis in Japanese patients with chronic liver diseases. Hepatol Res. 2013; 43: 1182-9

39）Jung KS, Kim BK, Kim SU, et al. Factors affecting the accuracy of controlled attenuation parameter (CAP) in assessing hepatic steatosis in patients with chronic liver disease. PLoS One. 2014; 9: e98689

40）Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005; 41: 1313-21

41）de Ledinghen V, Vergniol J, Capdepont M, et al. Controlled attenuation parameter (CAP) for the diagnosis of steatosis: a prospective study of 5323 examinations. J Hepatol. 2014; 60: 1026-31

42）Park YS, Park SH, Lee SS, et al. Biopsy-proven nonsteatotic liver in adults: estimation of reference range for difference in attenuation between the liver and the spleen at nonenhanced CT. Radiology. 2011; 258: 760-6

43）Fischer MA, Gnannt R, Raptis D, et al. Quantification of liver fat in the presence of iron and iodine: an ex-vivo dual-energy CT study. Invest Radiol. 2011; 46: 351-8

44）Hur BY, Lee JM, Hyunsik W, et al. Quantification of the Fat Fraction in the Liver Using Dual-Energy Computed Tomography and Multimaterial Decomposition. J Comput Assist Tomogr. 2014 Aug 26. [Epub ahead of print]

45）Mendonca P, Lamb P, Sahani D. A Flexible Method for Multi-Material Decomposition of Dual-Energy CT Images. IEEE Trans Med Imaging. 2013 Sep 16. [Epub ahead of print]

46）Ligabue G, Besutti G, Scaglioni R, et al. MR quantitative biomarkers of non-alcoholic fatty liver disease: technical evolutions and future trends. Quant Imaging Med Surg. 2013; 3: 192-5

47）Reeder SB, Cruite I, Hamilton G, et al. Quantitative assessment of liver fat with magnetic resonance imaging and spectroscopy. J Magn Reson Imaging. 2011; 34: 729-49

48）Hines CD, Agni R, Roen C, et al. Validation of MRI biomarkers of hepatic steatosis in the presence of iron overload in the ob/ob mouse. J Magn Reson Imaging. 2012; 35: 844-51

49）Kuhn JP, Hernando D, Mensel B, et al. Quantitative chemical shift-encoded MRI is an accurate method to quantify hepatic steatosis. J Magn Reson Imaging. 2014; 39: 1494-501

50）Kuhn JP, Hernando D, Munoz del Rio A, et al. Effect of multipeak spectral modeling of fat for liver iron and fat quantification: correlation of biopsy with MR imaging results. Radiology. 2012; 265: 133-42

51）Meisamy S, Hines CD, Hamilton G, et al. Quantification of hepatic steatosis with T1-independent, T2-corrected MR imaging with spectral modeling of fat: blinded comparison with MR spectroscopy. Radiology. 2011; 258: 767-75

52）Deng J, Fishbein MH, Rigsby CK, et al. Quantitative MRI for hepatic fat fraction and T2* measurement in pediatric patients with non-alcoholic fatty liver disease. Pediatr Radiol. 2014 May 20. [Epub ahead of print]

53）Hines CD, Frydrychowicz A, Hamilton G, et al. T(1) independent, T(2) (*) corrected chemical shift based fat-water separation with multi-peak fat spectral modeling is an accurate and precise measure of hepatic steatosis. J Magn Reson Imaging. 2011; 33: 873-81

54）Tang A, Tan J, Sun M, et al. Nonalcoholic fatty liver disease: MR imaging of liver proton density fat fraction to assess hepatic steatosis. Radiology. 2013; 267: 422-31

55）Awai HI, Newton KP, Sirlin CB, et al. Evidence and recommendations for imaging liver fat in children, based on systematic review. Clin Gastroenterol Hepatol. 2014; 12: 765-73

56）Permutt Z, Le TA, Peterson MR, et al. Correlation between liver histology and novel magnetic resonance imaging in adult patients with non-alcoholic fatty liver disease - MRI accurately quantifies hepatic steatosis in NAFLD. Aliment Pharmacol Ther. 2012; 36: 22-9

NPO医学中央雑誌刊行会 https://www.jamas.or.jp/ info@jamas.or.jp